Get the Stockscreener App
9.46
7.69%
0.62
Immix Biopharma Inc stock is traded at $9.46, with a volume of 421.11K.
It is up +7.69% in the last 24 hours and down -0.10% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.84
Open:
$8.86
24h Volume:
421.11K
Relative Volume:
0.47
Market Cap:
$673.46M
Revenue:
-
Net Income/Loss:
$-29.44M
P/E Ratio:
-10.62
EPS:
-0.8906
Net Cash Flow:
$-24.66M
1W Performance:
+6.49%
1M Performance:
-0.10%
6M Performance:
+121.40%
1Y Performance:
+383.25%
1-Day Range:
$8.67
$9.77
1-Week Range:
$8.005
$9.77
52-Week Range:
$1.87
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
9.46 | 629.32M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
444.45 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.70 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.77 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.69 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.29 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma closes $140.65 million offering - The Pharma Letter
Immix Biopharma stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
What's going on with Immix Biopharma stock Thursday? - MSN
Immix Biopharma Announces Closing of $150 Mil - Moomoo
Immix Biopharma closes $140.65 million stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma closes $140.65 million stock offering - Investing.com UK
IMMX Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common Stock - Quiver Quantitative
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Biotech Immix Biopharma pulls in $140.65M from new stock sale - Stock Titan
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright - TipRanks
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - Sahm
Immix Biopharma Announces $150 Million Stock Offering to Fund NXC-201 AL Amyloidosis Therapy Development - Minichart
Immix Biopharma Raises $150 Million to Advance NXC-201 - TipRanks
Immix Biopharma (NASDAQ: IMMX) prices $150M common stock sale - Stock Titan
Immix Biopharma (IMMX) to raise ~$140.7M net via 16.78M-share sale - Stock Titan
What's Going On With Immix Biopharma Stock Thursday? - Benzinga
Immix Biopharma Prices $150 Million Stock Offering - Moomoo
Sector Update: Healthcare - Moomoo
Immix Biopharma prices $150 million stock offering at $8.94 - Investing.com
Immix Biopharma Reports 95% Complete Response Rate in AL Amyloidosis Trial - Moomoo
Immix rises after mid-stage trial data for AL amyloidosis therapy - Seeking Alpha
Immix Biopharma Reports Strong Interim NXC-201 Phase 2 Data - TipRanks
Immix Biopharma prices $150 million stock offering at $8.94 By Investing.com - Investing.com Australia
Immix Biopharma announces pricing of $150 million underwritten offering of common stock - marketscreener.com
Immix Biopharma announces 95% complete response rate in interim update from relapsed/refractory AL amyloidosis clinical trial NEXICART-2 - marketscreener.com
Immix Biopharma reports 95% complete response rate in trial - Investing.com
Immix Biopharma Announces Pricing Of $150 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma prices $150M deal to fund NXC-201 work into 2028 - Stock Titan
Immix Biopharma reports 95% complete response rate in trial By Investing.com - Investing.com Canada
Immix Biopharma NEXICART-2 interim: 95% CR rate (19/20) as all MRD-negative patients convert - TradingView
Immix Biopharma Reports 95% Complete Response Rate in NEXICART-2 Trial for AL Amyloidosis Patients - Quiver Quantitative
Immix Biopharma (Nasdaq: IMMX) reports 95% CR in NEXICART-2, plans Phase 3 - Stock Titan
Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2 - marketscreener.com
Should You Sell Immix Biopharma (IMMX) After -2.48% Drop? 2026-05-20Certified Trade Ideas - Newser
Why Is Immix Biopharma, Inc. (IMMX) Stock Down Today? - Meyka
Immix Biopharma (IMMX) Q1 2026 Earnings: $-0.18 EPS Surges Past $-0.21 EstimatesSocial Investment Platform - Newser
Immix Biopharma (IMMX) Declines -1.58% Amid Market Weakness 2026-05-15MA Crossover - newser.com
Janus Henderson (IMMX) reports 4.8M shares, 9.1% stake disclosed - Stock Titan
IMMX Stock Price and Chart — NASDAQ:IMMX - TradingView
Immix Biopharma stock rating maintained at Market Outperform by Citizens - Investing.com Nigeria
Immix Biopharma, Inc. 2026 Q1 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immix Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immix Biopharma (NASDAQ: IMMX) Q1 loss widens but cash at $90.6M - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
What Immix Biopharma (IMMX) is doing that could pay off big later (Bearish Sentiment) 2026-05-07High Interest Stocks - Newser
Number of shareholders of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Immix Biopharma, Inc.Common Stock (NQ: IMMX - FinancialContent
Immix Biopharma Finishes NEXICART-2 Trial Enrollment for Amyloidosis - HarianBasis.co
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? - Insider Monkey
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
0.67%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):